Tirzepatide (Mounjaro®)

From 23 June, people living with obesity will be able to begin accessing tirzepatide (Mounjaro®) for weight loss purposes in primary care settings.

This campaign is intended for regional and ICBs comms teams, which will be managing local communications around the beginning of access to tirzepatide (Mounjaro®) across primary care settings. Campaign resources include a communications toolkit, FAQs, briefing note, narrative and social media assets (to follow).